Literature DB >> 19439015

Dynamic changes in biomarker profiles associated with clinical and subclinical tuberculosis in a high transmission setting: a four-year follow-up study.

N Talat1, F Shahid, G Dawood, R Hussain.   

Abstract

Mycobacterium tuberculosis (MTB) is a slow growing bacterium. Therefore, the immune responses associated with resolution of infection or development of disease post-exposure may take several months to evolve. We have carried out a prospective longitudinal study in a high TB transmission setting to determine the evolution of biomarkers in a recently exposed household contact (HC = 77) and their respective sputum positive index cases (TB = 17). Mycobacterium-induced cytokines [interferon-gamma (IFN-gamma), tumour necrosis factor-alpha, interleukin-6 (IL-6) and IL-10)] were assessed in whole blood cultures and immunoglobulin G (IgG1) antibodies in plasma. When compared with non-exposed community controls (endemic controls = 59) the HC group at intake showed changes in biomarkers commensurate with recent exposure. The HC group showed significant increases in IFN-gamma between 0 and 6 months (paired t-test; P = 0.001) and IL-0 between 6 and 12 months (P = 0.001), most likely reflecting the role of these cytokines in resolution and immune recovery from infection as this HC cohort remained symptom-free for 4 years without prophylactic treatment. When the TB group post-treatment was compared with the HC group, the best discriminators (ANOVA; repeated measures) were IL-10 responses at 0 (P = 0.004) and 6 months (P = 0.001) and IgG1 at 6 (P = 0.004) and 12 months (P = 0.014) with a 3-4 fold higher responses in the TB group. Therefore, within each group, biomarkers show unique profile of responses. These studies highlighted the importance of assessing multiple biomarkers in longitudinal studies for providing better understanding of protective biomarker profiles associated with resolution of clinical and subclinical infections in TB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19439015     DOI: 10.1111/j.1365-3083.2009.02250.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  5 in total

1.  Antibodies against immunodominant antigens of Mycobacterium tuberculosis in subjects with suspected tuberculosis in the United States compared by HIV status.

Authors:  Jacqueline M Achkar; Elisabeth Jenny-Avital; Xian Yu; Susanne Burger; Eric Leibert; Patrick W Bilder; Steven C Almo; Arturo Casadevall; Suman Laal
Journal:  Clin Vaccine Immunol       Date:  2010-01-13

2.  Endogenously activated interleukin-4 differentiates disease progressors and non-progressors in tuberculosis susceptible families: a 2-year biomarkers follow-up study.

Authors:  Rabia Hussain; Najeeha Talat; Ambreen Ansari; Firdaus Shahid; Zahra Hasan; Ghaffar Dawood
Journal:  J Clin Immunol       Date:  2011-07-14       Impact factor: 8.317

Review 3.  The immunology of tuberculosis: from bench to bedside.

Authors:  Keertan Dheda; Stephan K Schwander; Bingdong Zhu; Richard N van Zyl-Smit; Ying Zhang
Journal:  Respirology       Date:  2010-04       Impact factor: 6.424

4.  CCL2/MCP-I genotype-phenotype relationship in latent tuberculosis infection.

Authors:  Rabia Hussain; Ambreen Ansari; Najeeha Talat; Zahra Hasan; Ghaffar Dawood
Journal:  PLoS One       Date:  2011-10-04       Impact factor: 3.240

5.  Biomarker changes associated with Tuberculin Skin Test (TST) conversion: a two-year longitudinal follow-up study in exposed household contacts.

Authors:  Rabia Hussain; Najeeha Talat; Firdaus Shahid; Ghaffar Dawood
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.